Adverse Dermatologic Effects of Cardiovascular Drug Therapy

Heart Disease

Volumn 2, Issue 3, 2000, Pages 220-247

  Brosnan, Brian D ^a   Frishman, William H ^a   Sun, Diana K ^b   Grossman, Marc ^c  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT;

CARDIOVASCULAR DISEASE; HUMAN; IATROGENIC DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; SKIN; SKIN DISEASE;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; HUMAN; SKIN; SKIN DISEASES;

EID: 0034189585     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (432)

1. Sun DK, Reiner D, Frishman W, Grossman M. Adverse dermatologic reactions from antiarrhythmic drug therapy. J Clin Pharmacol 1994;34:953-966.
2. Aparasu RR. Visits to office-based physicians in the united states for medication-related morbidity. J Am Pharm Assoc 1999;39:332-337.
3. Kluger J, Drayer DE, Reidenberg MM, Lahita R. Acetylprocainamide therapy in patients with previous procainamide-induced lupus. Ann Intern Med 1981; 95:18-23.
4. Roden DM, Reele SB, Higgins SB, Wilkinson GR, Smith RF, Oates JA, Woosley RL. Antiarrythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide. Am J Cardiol 1980; 46:463-468.
5. Atkinson AJ Jr, Lertora JJ, Kushner W, Chao GC, Nevin MJ. Efficacy and safety of N-acetylprocainamide in long-term treatment of ventricular arrhythmias. Clin Pharm Ther 1983;33:565-576.
6. Lertora JJ, Atkinson AJ Jr, Kushner W, Nevin MJ, Lee WK, Jones C, Schmid FR. Long-term antiarrythmic therapy with N-acetylprocainamide. Clin Pharmacol Ther 1979;25:273-282.
7. Physicians Desk Reference. 50th edition. Montvale, NJ: Medical Economics Data, 1996.
8. Caron J, Libersa C. Adverse effects of class I antiarrhythmic drugs. Drug Safety 1997;1:8-36.
9. McEvoy GK (ed). American Hospital Formulary Service Drug Information 1991. Bethesda, MD: American Society of Hospital Pharmacists, 1991.
10. Physicians Desk Reference. 45th edition. Montvale, NJ: Medical Economics Data, 1991.
11. Mancuso G, Tampieri E, Berdondini RM. Psoriasis-like eruption caused by flecainide. G Ital Dermatol Venereol 1988;123:171-172.
12. Gentzkow GD, Sullivan JY. Extracardiac adverse effects of flecainide. Am J Cardiol 1984;53:101B-105B.
13. Palace I, Shah R, Clough C. Flecainide induced peripheral neuropathy. Br Med 1992;305:810.
14. Bricker SR, Raitt DG. Angioneurotic edema following etomidate lignocaine. Anaesthesia 1987;42:323-324.
15. McEvoy GK (ed). American Hospital Formulary Service Drug Information 1995. Bethesda, MD: American Society of Hospital Pharmacists, 1995.
16. Bartolomei FJ, Pearlstein T. Anaphylaxis (letter). J Am Podiatr Med Assoc 1990;80:665.
17. Black RJ, Dawson TA, Strang WC. Contact sensitivity to lignocaine and prilocaine. Contact Dermatitis 1990;23:117-118.
18. Van Der Bul P, Broekksma J. Acute bronchospasm following administration of lidocaine. Anesth Pain Control Dentistry 1993;2:203-205.
19. Physicians Desk Reference. 53rd edition. Montvale, NJ: Medical Economics Data, 1999.
20. Silverman AK, Fairley J, Wong RC. Cutaneous and immunologic reactions to phenytoin. J Am Acad Dermatol 1988;18:721-741.
21. Vivard I, Trechot P, Schmutz JL, Cuny JF, Weber M, Beurey J. Phenytoin and hirsutism. Ann Dermatol Venereol 1989;116:562.
22. Grunwald MH, Ben-Dor D, Livni E, Halevy S. Acne keloidalis-like lesions on the scalp associated with antiepileptic drugs. Int J Dermatol 1990;29:559-561.
23. Macleod SP, MacIntyre DR. Cutaneous reaction to phenytoin (letter). Br Dent J 1991;171:237.
24. Kleier RS, Breneman DL, Boiko S. Generalized pustulation as a manifestation of the anticonvulsant hypersensitivity syndrome. Arch Dermatol 1991;127: 1361-1364.
25. O'Brien TJ, Mason GH, Dorevitch AP. Widespread pustular eruption. Australas J Dermatol 1993;34:128-130.
26. Danno K, Kume M, Ohta M, Utani A, Ohno S, Kobashi Y. Erythroderma with generalized lymphadenopathy induced by phenytoin. J Dermatol 1989;16: 392-396.
27. Rowe JE, Pina J, Sau P, James W. Toxic epidermal necrolysis associated with diphenylhydantoin and cranial irradiation. Int J Dermatol 1991;30:747-749.
28. Kelly DR, Hope DG. Fatal phenytoin-related toxic epidermal necrolysis: case report. Neurosurgery 1989;25:976-978.
29. Gately LE, Lam M. Phenytoin-induced toxic epidermal necrolysis. Ann Intern Med 1979;91:59-60.
30. D'Incan M, Souteyrand P, Bignon YJ, Fonck Y, Roger H. Hydantoin-induced cutaneous pseudolymphoma with clinical, pathologic, and immunologic aspects of Sézary's syndrome. Arch Dermatol 1992;128:1371-1374.
31. Norris JF, Cunliffe WJ. Phenytoin-induced gum hypertrophy improved by isoretinoin. Int J Dermatol 1987;26:602-603.
32. McLoughlin P, Newman L, Brown A. Oral squamous cell carcinoma arising in phenytoin-induced hyperplasia. Br Dent J 1995;178:183-184.
33. Goldstein N, Leider M, Baer RL. Drug eruptions from anticonvulsant drugs. Arch Dermatol 1963;87:613-620.
34. Finan E, Trofa A, Williams K. Phenytoin hypersensitivity. Md State Med J 1990;39:589-591.
35. Stanley J, Fallon-Pellicci V. Phenytoin hypersensitivity reaction. Arch Dermatol 1978;114:1350-1353.
36. Rosenthal CJ, Noguera CA, Coppola A, Kapelner S. Pseudolymphoma with mycosis fungoides manifestations, hyperresponsiveness to diphenylhydantoin, and lymphocyte disregulation. Cancer 1982;49:2305-2314.
37. Braddock SW, Harrington D, Vose J. Generalized nodular cutaneous pseudolymphoma associated with phenytoin therapy: use of T-cell receptor gene rearrangement in diagnosis and clinical review of cutaneous reactions to phenytoin. J Am Acad Dermatol 1992;27:337-340.
38. Adams JD. Localized cutaneous pseudolymphoma associated with phenytoin therapy: a case report. Australas J Dermatol 1981;22:28-29.
39. Rijlaarsdam U, Scheffer E, Meijer CJ, Kruyswijk MR, Willemze R. Mycosis-fungoides-like lesions associated with phenytoin and carbamazepine therapy. J Am Acad Dermatol 1991;24:216-220.
40. Schreiber MM, McGregor JG. Pseudolymphoma syndrome: a sensitivity to anticonvulsant drugs. Arch Dermatol 1968;97:297-300.
41. Souteyrand P, D'Incan M. Drug-induced mycosis fungoides-like lesions. Curr Probl Dermatol 1990;19:176-182.
42. Harris DW, Ostlere L, Buckley G, Whittaker S, Sweny P, Rustin MH. Phenytoin-induced pseudolymphonia: a report of a case and review of the literature. Br J Dermatol 1992;127:403-406.
43. Doyle MF, Anderson S, Cerrezuela G, Gabrail N. Sézary syndrome associated with phenytoin therapy. Acta Haematol 1994;92:204-207.
44. Hanna DR. Purple glove syndrome: a complication of intravenous phenytoin. J Neurosci Nurs 1992;24:340-345.
45. Parodi M. Systemic lupus erythematosus induced by drugs. Minerva Med 1990;81(Suppl 7-8):97-107.
46. Stevens MB. Drug-induced lupus. Hosp Pract 1992;27:27-36.
47. Uetrecht JP. Mechanism of drug-induced lupus. Chem Res Toxicol 1988;1: 133-143.
48. Oliphant L, Goddard M. Tocainide-associated neutropenia and the lupus-like syndrome. Chest 1988;94:427-428.
49. Schurer NY, Lehmann P, Plewig G. Quinidine-induced photoallergy: a clinical and experimental study. Hautarzt 1991;42:158-161.
50. Smith PR, Nacht RI. Drug-induced lupus pleuritis mimicking pleural space infection. Chest 1992;101:268-269.
51. Finger DR, Bernet VJ, Doyle JJ. Polyglandular autoimmune endocrinopathy following procainamide induced lupus. J Rheumatol 1995;22:574-575.
52. MacDonal E, Marino C. Procainamide-induced lupus in the elderly. Hosp Pract 1993;28:95-98.
53. Rubin RL, Burlingame RW, Arnott JE, Totoritis MC, McNally EM, Johnson AD. IgG but not other classes of anti-[(H2A-H2B)-DNA] is an early sign of procainamide-induced lupus. J Immunol 1995;154:2483-2493.
54. Lucches BR, Lynch J. Pharmacology of antiarrythmic drugs. In: Craig CR, Stitzel RE (eds). Modern Pharmacology. Second edition. Boston: Little, Brown, 1986;393-000.
55. Sherertz EF. Lichen planus following procainamide-induced lupus erythematosus. Cutis 1988;42:51-53.
56. Rosin JM. Vasculitis following procainamide therapy. Am J Med 1967;42: 625-629.
57. Knox JP, Welykyj SE, Gradini R, Massa MC. Procainamide induced urticarial vasculitis. Cutis 1988;42:469-472.
58. Ladd AT. Procainamide-induced lupus erythematosus. N Engl J Med 1962; 267:1357-1358.
59. Landrum EM, Siegert EA, Hanlon JT, Currie MS. Prolonged thrombocytopenia associated with procainamide in an elderly patient. Ann Pharmacother 1994;28:1172-1176.
60. Freeman NJ, Fajardo L, Carvalho A. Simultaneous procainamide-induced immune thrombocytopenia and lupus anticoagulant. Am J Hematol 1995;48: 133-134.
61. Chuang LC, Tunier AP, Akhtar N, Levine SM. Possible case of procainamide-induced intrahepatic cholestatic jaundice. Ann Pharmacother 1993;27:434-437.
62. Worman HJ, Ip JH, Winters SL, Tepper DC, Gomes AJ. Hypersensitivity reaction associated with acute hepatic dysfunction following a single intravenous dose of procainamide. J Int Med 1992;232:361-363.
63. Guindo J, Rodriguez A, Borja J, Oter R, Jane F, Bayes-de-Luna A. Propafenone and a syndrome of the lupus erythematosus type. Ann Intern Med 1986;104:589.
64. Staughton R, Sutton R, Farrel M. β-blockers, autoimmunity and rashes (letter). Lancet 1980;2:581.
65. Pariser DM, Taylor JR. Quinidine photosensitivity. Arch Dermatol 1975;111: 1440-1443.
66. Nudelman PL, Leff IL, Howe CD. Thrombocytopenic purpura following quinidine. JAMA 1948;137:1219-1220.
67. Marion DF, Terrieri C. Photosensitive livedo reticularis. Arch Dermatol 1973; 108:100-101.
68. Shalit M, Flugelman MY, Harats N, Galun E, Ackerman Z, Kopolovic J, Eliakim M. Quinidine-induced vasculitis. Arch Intern Med 1985;145:2051-2052.
69. Taylor DR, Potashnick R. Quinidine-induced exfoliative dermatitis. JAMA 1951;145:641-642.
70. de Larrard G, Jeanmougin M, Moulonguet I, Maillet M, Civatte J. Lichenoid dermatitis with alopecia caused by quinidine. Ann Dermatol Venereol 1988; 115:1172-1173.
71. Brenner S, Cabili S, Wolf R. Widespread crythematous scaly plaques in an adult: psoriasiform eruption induced by quinidine. Arch Dermatol 1993;129: 1331-1335.
72. Cohen M, Sumant K, Prowse M, Ahern M. Two distinct quinidine-induced rheumatic syndromes. Ann Intern Med 1988;108:369-371.
73. Tebas P, Lozano I, de la Fuente J, Ortigosa J, Perez Maestu R, Masa C, de Letona JM. Lupus induced by quinidine. Rev Clin Esp 1991;189:123-124.
74. Selvaag E. Clinical drug photosensitivity: a retrospective analysis of reports to the Norwegian adverse drug reactions committee from the years 1970-1994. Photodermatol Photoimmunol Photomed 1997;13:21-23.
75. Manzi S, Kraus VB, St. Clair W. An unusual photoactivated skin eruption. Arch Dermatol 1989;125:417-418, 421-422.
76. Petersen CS, Thomsen K. Pseudoporphyria. Ugeskr-Laeger 1992;154:1713-1715.
77. Mahler R, Sissons W, Watters K. Pigmentation induced by quinidine therapy. Arch Dermatol 1986;122:1062-1064.
78. Fitzpatrick JE. New histopathologic findings in drug eruptions. Dermatol Clin 1992;10:19-36.
79. Birek C, Main JH. Two cases of oral pigmentation associated with quinidine therapy. Oral Surg 1988;66:59-61.
80. Sarkany I. Lichen planus following quinidine therapy. Br J Dermatol 1967;79: 123.
81. Bonnetblane JM, Bernard P, Catanzano G, Souyri N. Quinidine-induced lichenoid photodermatitis. Ann Dermatol Venereol 1987;114:957-961.
82. Wolf R, Dorfman B, Krakowski A. Quinidine-induced lichenoid and eczematous photodermatitis. Dermatologica 1987;174:285-289.
83. Lever WF, Schaumburg-Lever G. Histopathology of the Skin. Seventh edition. Philadelphia: JB Lippincott, 1990.
84. Zax R, Hodge S, Callen J. Cutaneous leukocytoclastic vasculitis. Arch Dermatol 1990;126:69-72.
85. Quin J, Adamski M, Howlin K, Jones W, O'Neill P, Stewart G, Young A. Quinidine-induced allergic granulomatous angiitis: an unusual cause of acute renal failure. Med J Aust 1988;148:145-146.
86. Nieminen U, Kekomaki R. Quinidine-induced thrombocytopenic purpura: clinical presentation in relation to drug-dependent and drug-independent platelet antibodies. Br J Haematol 1992;80:77-82.
87. Maslanka K, Majcher A, Bykowska K. Quinidine-induced thrombocytopenia. Acta Haematol Pol 1991;22:154-159.
88. Visentin GP, Newman PJ, Aster RH. Characteristics of quinine- and quinidine-induced antibodies specific for platelet glycoproteins IIb and IIIa. Blood 1991; 77:2668-2676.
89. Arrowsmith JB, Creamer JI, Bosco L. Severe dermatologic reactions reported after treatment with tocainide. Ann Intern Med 1987;107:693-696.
90. Mahapatra R, Mahapatra D. Efficacy and safety of oral tocainide in refractory ventricular arrythmia: a preliminary report on an open-label study. Angiology 1986;347:285-293.
91. Roden DM, Woosley RL. Tocainide. N Engl J Med 1986;315:41-45.
92. Dunn JM, Groth PE, DeSimone A. Tocainide: a severe adverse reaction. Drug Intell Clin Pharm 1988;22:142-145.
93. Duff HJ, Roden DM, Marney S, Colley DG, Maffucci R, Primm RK, et al. Molecular basis for the antigenicity of lidocaine analogs: tocainide and mexilitine. Am Heart J 1984;107:585-589.
94. Taylor AE, Hindson C, Wacks H. A drug eruption due to acebutolol with combined lichenoid and lupus erythematosus features. Clin Exp Dermatol 1982;7:219-221.
95. Cody RJ Jr, Calabrese LH, Clough JD, Tarazi RC, Bravo EL. Development of antinuclear antibodies during acebutolol therapy. Clin Pharmacol Ther 1979; 25:800-805.
96. Cavicchini S, Brezzi A, Gianotti R. Atenolol-induced psoriasiform dermatitis. G Ital Dermatol Venereol 1990;125:337-339.
97. Wakefield PE, Berger TG, James WD. Atenolol-induced pustular psoriasis. Arch Dermatol 1990;126:968-969.
98. Gawkrodger DJ, Beveridge GW. Psoriasiform reaction to atenolol. Clin Exp Dermatol 1984;9:92-94.
99. Harrison PV, Rowell NR. Atenolol causing cutaneous eruption. Clin Exp Dermatol 1979;4:547-548.
100. Wolf R, Ophir J, Elman M, Krakowski A. Atenolol-induced cutaneous vasculitis. Cutis 1989;43:231-233.
101. Gokal R, Dorman TL, Ledingham JGG. Peripheral skin necrosis complicating beta blockage. Br Med J 1979;1:721-722.
102. GenRx. Physicians Online. St. Louis: Mosby, 1996.
103. Brown RC, Cooke J, Losowsky MS. SLE syndrome, probably induced by labetalol. Postgrad Med 1981;157:189-190.
104. Griffiths ID, Richardson J. Lupus-type illness associated with labetalol. Br Med J 1979;12:496-497.
105. Grange RW, Jones EW. Bullous lichen planus caused by labetalol. Br Med J 1978;1:816-817.
106. Neumann HAM, van Joost T. Adverse reactions of the skin to metoprolol and other beta-adrenoreceptor blocking agents. Dermatologica 1981;162:330-335.
107. Graeber CW, Lapkin RA. Metoprolol and alopecia. Cutis 1981;28:633-634.
108. McEvoy GK (ed). American Hospital Formulary Service Drug Information 1998. Bethesda, MD: American Society of Hospital Pharmacists, 1998.
109. Leonard JC. Oxprenolol and a psoriasis-like eruption. Lancet 1975;1:630.
110. Harrower ADB, Strong JA. Hyperpigmentation associated with oxprenolol administration. Br Med J 1977;2:296.
111. Holt PJA, Waddington E. Oculocutaneous reaction to oxprenolol. Br Med J 1975;12:539-540.
112. Waal-Manning HJ. Problems with practolol. Drugs 1975;10:336-341.
113. Almeyda J, Levantine A. Cutaneous reactions to cardiovascular drugs. Br J Dermatol 1973;88:313-319.
114. Wright P. Unwanted effects associated with practolol administration: oculomucocutaneous syndrome. Br Med J 1975;1:595-598.
115. Felix RH, Ive FA, Dahl MCG. Cutaneous and ocular reactions to practolol. Br Med J 1974;4:321-324.
116. Stephen SA. Unwanted effects of propranolol. Am J Cardiol 1966;18:463-472.
117. Cochran RI, Thomson J, McQueen A. Skin reactions associated with propranolol. Arch Dermatol 1976;112:1173-1174.
118. Jensen HA, Mikkelsen HI, Wadskov S, Sondergaard J. Cutaneous reactions to propranolol (Inderal). Acta Med Scand 1976;199:363-367.
119. Massa MC, Jason SM, Gradini R, Welykyj S. Lichenoid drug eruption secondary to propranolol. Cutis 1991;48:41-43.
120. Halevy S, Livni E. Psoriasis and psoriasiform eruptions associated with propranolol the role of an immunological mechanism. Arch Dermatol Res 1991; 283:472-473.
121. Steinkraus V, Steinfath M, Mensing H. β-adrenergic blocking drugs and psoriasis. J Am Acad Dermatol 1992;27:266-267.
122. Halevy S, Livni E. Beta-adrenergic blocking drugs and psoriasis: the role of an immunologic mechanism. J Am Acad Dermatol 1993;29:504-505.
123. Hu CH, Peppercorn R, Farber EM. Generalized pustular psoriasis provoked by propranolol. Arch Dermatol 1985;212:1326-1327.
124. Martinez-Mir I, Navarro-Badenes J, Palop V, Morales-Olivas FJ, Rubio E. Weight gain induced by long-term propranolol treatment (letter). Ann Pharmacother 1993;27:512.
125. Friedman M. Iatrogenic alopecia. J Fam Pract 1994;39:114.
126. Martin CM, Southwick E, Maibach H. Propranolol-induced alopecia. Am Heart J 1973;86:236-237.
127. Harrison T, Sisca T, Wood W. Case report: propranolol-induced lupus syndrome? Postgrad Med 1976;59:241-244.
128. Zacharias FJ, Cowen KJ, Prestt J, Vickers J, Wall BG. Propranolol in hypertension: a study of long term therapy, 1964-1970. Am Heart J 1972;83:755-761.
129. Mukul VG, Verma G. Propranolol-induced Stevens-Johnson syndrome. J Assoc Phys India 1989;37:797-798.
130. Zukervar P, Vial T, Jay P, Delcombel M, Descotes J. The Stevens-Johnson syndrome from maprotiline and propranolol? J Toxicol Clin Exp 1990;10:169-172.
131. Singh BN, Deedwania P, Nademanee K, Ward A, Sorkin EM. Sotalol: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 1987;34:311-349.
132. O'Brien TJ, Lyall IG, Reid SS. Lichenoid eruption by sotalol. Australas J Dermatol 1994;35:93-94.
133. Tisdale JE, Follin SL, Ordelova A, Webb CR. Risk factors for the development of specific noncardiovascular adverse effects associated with amiodarone. J Clin Pharmacol 1995;35:351-356.
134. Rappersberger K, Honigsmann H, Ortel B, Tanew A, Konrad K, Wolff K. Photosensitivity and hyperpigmentation in amiodarone-treated patients: incidence, time course and recovery. J Invest Dermatol 1989;93:201-209.
135. Harris L, McKenna WJ, Rowland E, Holt DW, Storey GC, Krikler DM. Side effects of long-term amiodarone therapy. Circulation 1983;67:45-51.
136. Wilson JS, Podrid PJ. Side effects from ainiodarone. Am Heart J 1991;121: 158-171.
137. Roupe G, Larke O, Olsson SB. Amiodarone photoreactions. Acta Derm Venereol (Stockholm) 1987;67:76-79.
138. Feigl D, Gilad R, Katz E. Complications of low-dose amiodarone. Harefuah 1991;121:374-377.
139. Blacksheer JL, Randle HW. Reversibility of blue-gray cutaneous discoloration from amiodarone. Mayo Clin Proc 1991;66:72 1-726.
140. Klein AD, Pardo R, Gould E. Blue-gray discoloration of the face. Arch Dermatol 1989;125:417, 420-421.
141. Davies DM, Ferner, RE, de Glanville H. Davies' Textbook of Adverse Drug Reactions. Fifth edition. New York: Lippincott-Raven, 1998.
142. Beukema WP, Graboys TB. Spontaneous disappearance of blue-gray facial pigmentation during amiodarone therapy. Am J Cardiol 1988;62:1146-1147.
143. Hilleman D, Miller MA, Parker R, Doering P, Pieper JA. Optimal management of amiodarone therapy: efficacy and side effects. Pharmacotherapy 1998; 18:138S-145S.
144. Porters JE, Zantkuyl CF. Ioderma caused by amiodarone. Arch Dermatol 1975;111:1656.
145. Reifler DM, Verdier DD, Daw CL, Mostow ND, Wendt VE. Multiple chalazia and rosacea in a patient treated with amiodarone. Am J Ophthalmol 1987;103: 594-595.
146. Ahmad S. Amiodarone and reversible alopecia (letter). Arch Intern Med 1995; 155:1106.
147. Primka EJ III, Liranzo MO, Bergfeld WF, Dijkstra JW. Amiodarone-induced linear IgA disease. J Am Acad Dermatol 1994;31:809-811.
148. Moots RJ, Banerjee A. Exfoliative dermatitis after amiodarone treatment. Br Med J 1988;296:1332-1333.
149. Staubi M, Zimmermann A, Bircher J. Amiodarone-induced vasculitis and polyserositis. Postgrad Med J 1985;61:245-247.
150. Gutierrez R, Del Pozo J, Carrion C, De Lucas R, Garcia B, Casado M, Jimenez E. Vasculitis associated with amiodarone treatment (letter). Ann Pharmacother 1994;28:537.
151. Khanderia U, Jaffe CA, Theisen V. Amiodarone-induced thyroid dysfunction. Clin Pharm 1993;12:774-779.
152. Trip MD, Wiiersinga W, Plomp TA. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med 1991;91:507-511.
153. 53. Dougall HT, McLay J. A comparative review of the adverse effects of calcium antagonists. Drug Safety 1996;15:91-106.
154. Kitamura K, Kanasashi M, Suga C., Saito S, Yoshida S, Ikezawa Z. Cutaneous reactions induced by calcium channel blockers: high frequency of psoriasiform eruptions. J Dermatol 1993;20:279-286.
155. Seymour RA. Calcium channel blockers and gingival overgrowth. Br Dent J 1991;170:376-379.
156. Lawrence DB, Weart CW, Laro JJ, Neville BW. Calcium channel blocker-induced gingival hyperplasia: case report and review of this iatrogenic disease. J Fam Pract 1994;39:483-488.
157. Nyska A, Shemesh M, Tal H, Dayan D. Gingival hyperplasia induced by calcium channel blockers: mode of action. Med Hypotheses 1994;43:115-118.
158. Thompson DF, Carter JR. Drug-induced gynecomastia. Pharmacotherapy 1993;13:37-45.
159. Boyd IW. Adverse Drug Reactions Advisory Committee: gynaecomastia in association with calcium antagonists. Med J Aust 1994;161:328.
160. Smith RG. Gingival enlargement in a patient medicated with amlodipine. Br Dent J 1993;175:279.
161. Seymour RA, Ellis JS, Thomason JM, Monkman S, Idle JR. Amlodipine-induced gingival overgrowth. J Clin Periodontol 1994;21:281-283.
162. Zochling J, Large G, Fassett R. Gynaecomastia and amlodipine (letter). Med J Aust 1994;160:807.
163. Dacosta A, Mismwtti P, Tardy B, Guy C, Zeni F, Rachet F, et al. Nonthrombopenic purpura induced by amlodipine. Therapie 1994;49:515-517.
164. Bewley AP, Feher MD, Staughton RC. Erythema multiforme following substitution of amlodipine for nifedipine. Br Med J 1991;307:241.
165. Wittal RA, Fischer GO, Georgouras KE, Baird PJ. Skin reactions to diltiazem. Australas J Dermatol 1992;33:11-18.
166. Sadick NS, Katz A, Schreiber T. Angioedema from calcium channel blockers. J Am Acad Dermatol 1989;21:132-133.
167. Lavijsen APM, Van Dijke C, Vermeer BJ. Diltiazem-associated exfoliative dermatitis in a patient with psoriasis. Acta Derm Venereol 1986;66:536-538.
168. Wakeel RA, Gavin MP, Keefe M. Severe toxic erythema caused by diltiazem. Br Med J 1988;1296:1071-1072.
169. Sanders CJ, Neumann HA. Erythema multiforme, Stevens-Johnson syndrome, and diltiazem (letter). Lancet 1993;341:967.
170. Lambert DG, Dalac S, Beer F, Chavannet P, Portier H. Acute generalized exanthematous pustular dermatitis induced by diltiazem. Br J Dermatol 1988; 118:308-309.
171. Wakelin SH, James MP. Diltiazem-induced acute generalised exanthematous pustulosis. Clin Exp Dermatol 1995;20:341-344.
172. Janier M, Gerault MH, Carlotti A, Vignon MD, Daniel F. Acute generalized exanthematous pustulosis due to diltiazem. Br J Dermatol 1993;129:354-355.
173. Sousa-Basto A, Azenha A, Duarte ML, Pardal-Oliveira F. Generalized cutaneous reaction to diltiazem. Contact Dermatitis 1993;29:44-45.
174. Odeh M. Exfoliative dermatitis associated with diltiazem. Clin Toxicol 1997; 35:101-104.
175. Sheehan-Dare RA, Goodfield MJD. Widespread cutaneous vasculitis associated with diltiazem. Postgrad Med J 1988;64:467-468.
176. Carmichael AJ, Paul CJ. Vasculitic leg ulcers with diltiazem. Br Med J 1988; 1297:562.
177. Crowson AN, Magro CN. Subacute cutaneous lupus erythematosus arising in the setting of calcium channel blocker therapy. Hum Pathol 1997;28:67-73.
178. Dominguez EA, Hamill RJ. Drug-induced fever due to diltiazem. Arch Intern Med 1991;151:1869-1879.
179. Friedland S, Kaplan S, Lahav M, Shapiro A. Proptosis and periorbital edema due to diltiazem treatment. Arch Ophthalmol 1993;111:1027-1028.
180. Knowles S, Gupta AK, Shear NH. The spectrum of cutaneous reactions associated with diltiazem: three eases and a review of the literature. J Am Acad Dermatol 1998;38:201-206.
181. Kuo M, Winiarski N, Garella S. Nonthrombocytopenic purpura associated sequentially with nifedipine and diltiazem. Ann Pharmacother 1992;26:1089-1090.
182. Barclay S, Thomason JM, Idle IR, Seymour RA. The incidence and severity of nifedipine-induced gingival overgrowth. J Clin Periodontol 1992;19:311-314.
183. Katz J, Rotstein I, Ben Yehuda A, Barak S. Nifedipine-induced gingival hyperplasia. Ann Dent 1992;51:5-7.
184. Parish LC, Witkowski JA. Truncal morbilliform eruption due to nifedipine. Cutis 1992;49:113-114.
185. Fisher JR, Padnick MB, Olstein S. Nifedipine and erythromyalgia. Ann Intern Med 1983;98:671-672.
186. Bridgeman JF. Erythematous edema of the legs due to nifedipine use. Br Med J 1978;1:578.
187. Thomas SE, Wood ML. Photosensitivity reactions associated with nifedipine. Br Med J 1986;292:992.
188. Collins P, Ferguson J. Photodistributed nifedipine-induced facial telangiectasia. Br J Dermatol 1993;129:630-633.
189. Tsele E, Chu AC. Nifedipine and telangiectasias. Lancet 1992;339:365-366.
190. Zenarola P, Gatti S, Lomuto M. Photodermatitis due to nifedipine: report of two cases. Dermatologica 1991;182:196-198.
191. Reynolds NJ, Jones SK, Crossley J, Harman RR. Exfoliative dermatitis due to nifedipine. Br J Dermatol 1989;121:401-404.
192. Mohammed KN. Nifedipine-induced exfoliative dermatitis and pedal edema (letter). Ann Pharmacother 1994;28:967.
193. Alclay J, David M, Sandbank M. Cutaneous reactions to nifedipine. Dermatology 1987;175:171-193.
194. Kim SC, Won JH, Ahn SK. Pemphigus foliaceus induced by nifedipine. Acta Derm Venereol 1993;73:210-211.
195. Brenner S, Brau S. Vasculitis following nifedipine. Harefuah 1985;108:139-140.
196. Breda E, Temperelli L, Sidoti AM, Pauselli F. Nifedipine and thrombocytopenia. Postgrad Med J 1992;168:769-770.
197. Tordjman K, Rosenthal T, Bursztyn M. Nifedipine induced periorbital edema. Am J Cardiol 1985;55:1445.
198. Silverstone PH. Periorbital oedema caused by nifedipine. Br Med J 1984;288: 1654.
199. Fujii A, Matsumoto H, Nakao S. Effect of calcium-channel blockers on cell proliferation, DNA synthesis, and collagen synthesis of cultured gingival fibroblasts derived from human nifedipine responders and non-responders. Arch Oral Biol 1994;39:99-104.
200. Bullon P, Machuca G, Martinez-Sahuquillo A, Rios JV, Rojas J, Lacalle JR. Clinical assessment of gingival hyperplasia on patients treated with nifedipine. J Clin Periodontol 1994;21:256-259.
201. Miller CS, Damm DD. Incidence of verapamil-mdueed gingival hyperplasia in a dental population. J Periodontol 1992;63:453-456.
202. Sever PS. Hypertrichosis and verapamil. Lancet 1991;338:1215-1216.
203. Stern R, Khalsa JH. Cutaneous adverse reaction associated with calcium channel blockers. Arch Intern Med 1989;149:829-832.
204. Kurkcuoglu N, Alaybeyi F. Erythema multiforme after verapamil treatment. J Am Acad Dermatol 1991;24:511-512.
205. Lin AYF, Baker BA. Verapamil-associated Stevens-Johnson syndrome. Drug Intell Clin Pharm 1989;23:987-988.
206. Drenth JP, Michiels JJ, Van Joost T, Vuzevski VD. Verapamil-induced secondary erythermalgia. Br J Dermatol 1992;127:292-294.
207. DiMarco JP, Sellers TD, Berne RM, West GA, Belardinelli L. Adenosine: electrophysiologic effects and therapeutic use for terminating paroxysmal supraventricular tachycardia. Circulation 1983;68:1254-1263.
208. Griffith MJ, Ward DE, Linker NJ, Camm AJ. Adenosine in the diagnosis of broad complex tachycardia. Lancet 1988;1:672-675.
209. Overholt ED, Rheuban KS, Gutgesell HP, Lerman BB, DiMarco JP. Usefulness of adenosine for arrythmias in infants and children. Am J Cardiol 1988; 61:336-340.
210. Berger H. Thrombocytopenic purpura following use of digoxin. JAMA 1952; 18:282.
211. David M, Livni E, Stern F, Feuerman EJ, Grinblatt J. Psoriasiform eruption induced by digoxin: confirmed by reexposure. J Am Acad Dermatol 1981;5: 702-703.
212. Goodfield MJ, Millard LG. Severe cutaneous reactions to captopril. Br Med J 1985;290:1111.
213. Atkinson AB, Robertson JS. Captopril in the treatment of clinical hypertension and cardiac failure. Lancet 1979;2:836-839.
214. Kayanakis JG, Giraud P, Fauvel JM, Bounhoure JP. Eosinophilia during captopril treatment (letter). Lancet 1980;2:923.
215. Solinger AM. Exfoliative dermatitis from captopril. Cutis 1982;29:473-474.
216. Slater EE, Merrill DD, Guess HA, Roylance PJ, Cooper WD, Inman WH, Ewan PW. Clinical profile of angioedema associated with angiotensin converting enzyme inhibition. JAMA 1988;260:967-970.
217. Chu TJ, Chow N. Adverse effects of ACE inhibitors (letter). Ann Intern Med 1993;118:314 (discussion 315).
218. Finley CJ, Silverman MA, Nunez AE. Angiotensin-converting enzyme inhibitor-induced angioedema: still unrecognized. Am J Emerg Med 1992;10:550-552.
219. Jason DR. Fatal angioedema associated with captopril. J Forensic Sci 1992;37: 1418-1421.
220. Schiller PI, Langauer MS, Haefeli WE, Schlienger RG, Bircher AJ. Angiotensin-converting enzyme inhibitor-induced angioedema: late onset, irregular course, and potential role of triggers. Allergy 1997;52:432-435.
221. Wolverton SE. Update on cutaneous drug reactions. Adv Dermatol 1998;13: 65-84.
222. Roberts JR, Wuerz RC. Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema. Ann Emerg Med 1991;20:555-558.
223. Thompson T, Frable MA. Drug-induced, life-threatening angioedema revisited. Laryngoscope 1993;103:10-12.
224. McElligott S, Perlroth M, Raish L. Angioedema after substituting lisinopril for captopril. Ann Intern Med 1992;116:426-427.
225. Cox NH, Tapson JS, Farr PM. Lichen planus-associated with captopril: a further disorder demonstrating the "tin-tack" sign. Br J Dermatol 1989;120: 319-321.
226. Wong SS, Long CC, Holt PJ. Lichenoid eruption induced by low dose captopril. Acta Derm Venereol 1992;72:358-359.
227. Phillips WG, Vaughn-Jones S, Jenkins R, Breathnach SM. Captopril-induced lichenoid eruption. Clin Exp Dermatol 1994;19:317-320.
228. Bruce F. Could it be a drug eruption? Aust Fam Physician 1997;26:689-695.
229. Kaplan RP, Callen JP. Pemphigus associated diseases and induced pemphigus. Clin Dermatol 1983;1:42-71.
230. Butt A, Burge SM. Pemphigus vulgaris induced by captopril. Br J Dermatol 1995;132:315-316.
231. Parfrey PS, Clement M, Vandenburg MJ, Wright P. Captopril-induced pemphigus. Br Med J 1980;281:194.
232. Kucchle MK, Hutton KP, Muller SA. Angiotensin-converting enzyme inhibitor-induced pemphigus: three case reports and literature review. Mayo Clin Proc 1994;69:1166-1171.
233. Korman NJ, Eyre RW, Zone J, Stanley JR. Drug-induced pemphigus: autoantibodies directed against the pemphigus antigen complexes are present in penicillamine and captopril-induced pemphigus. J Invest Dermatol 1991;96: 273-276.
234. Ruocco V, Satriano RA, Guerrera Y. "Two-step" pemphigus induction by ACE-inhibitors. Int J Dermatol 1992;31:33-36.
235. Pinto GM, Lamarao P, Vale T. Captopril-induced pemphigus vegetans with Charcot-Leyden crystals. J Am Acad Dermatol 1992;27:281-284.
236. Kaplan RT, PotterTS, Fox JN. Drug-induced pemphigus related to angiotensin-converting enzyme inhibitors. J Am Acad Dermatol 1992;26:364-366.
237. Wolf R, Brenner S. An active amide group in the molecule of drugs that induce pemphigus: a casual or causal relationship? Dermatology 1994;189:1-4.
238. Bastiaens MT, Zwan NV, Verschueren GL, Stoof TJ, Nieboer C. Three cases of pemphigus vegetans: induction by enalapril-association with internal malignancy. Int J Dermatol 1994;33:168-171.
239. Fitzgerald DA. Subepidermal bullous eruption induced by captopril. Clin Exp Dermatol 1993;18:196-197.
240. Flageul B, Foldes C, Wallach D, Vignon-Pennamen MD, Cottenot F. Captopril-induced lichen planus pemphigoides with pemphigus-like features. Dermatologica 1986;173:248-255.
241. Wilkin JK, Kirkendall WM. Pityriasis rosea-like rash from captopril. Arch Dermatol 1982;118:186-187.
242. Wood SM, Mann RD. Angioedema and urticaria associated with angiotensin converting enzyme inhibitors. Br Med J 1987;294:91-92.
243. Borders JV. Captopril and onycholysis. Ann Intern Med 1986;105:305-306.
244. Lluch-Bernal M, Novalbos A, Umpierrez A, Figueredo E, Bombin C, Sastre J. Cutaneous reaction to captopril with positive patch test and lack of cross-sensitivity to enalapril and benazepril. Contact Dermatitis 1998;39:316-317.
245. Bork K. Cutaneous Side Effects of Drugs. Philadelphia: WB Saunders, 1988.
246. Patri P, Nigro A, Rebora A. Lupus crythematosus-like eruption from captopril. Acta Derm Venereol 1985;65:447-448.
247. Tamir A, Wolf R, Brenner S. Exacerbation and induction of psoriasis by angiotensin-converting enzyme inhibitors (letter). J Am Acad Dermatol 1994; 30:1045.
248. Gilleaudeau P, Vallet VP, Carter DM, Gottlieb AB. Angiotensin-converting enzyme inhibitors as possible exacerbating drugs in psoriasis. J Am Acad Dermatol 1993;28:490-492.
249. Coulter DM, Pillans PI. Angiotensin-converting enzyme inhibitors and psoriasis. New Zealand Med J 1993;106:392-393.
250. Ikai K. Exacerbation and induction of psoriasis by angiotensin-converting enzyme inhibitors (letter). J Am Acad Dermatol 1995;32:819.
251. Bertin P, Kamdem J, Bonnet C, Arnaud M, Treves R. Captopril-induced lupus. Clin Exp Rheumatol 1993;11:695.
252. Stone KE, Moore ME. An ill woman with SLE who got worse with treatment. Hosp Pract 1991;26:57-60.
253. Pelayo M, Vargas V, Gonzales A, Vallano A, Esteban R, Guardia J. Drug-induced lupus-like reaction and captopril. Ann Pharmacother 1993;27:1541-1542.
254. Miralles R, Pedro-Botet J, Farre M, Rubies-Prat J. Captopril and vasculitis (letter). Ann Intern Med 1988;109:514.
255. Neumann J, Andrassy K, Walter-Sack I, Berg PA. Henoch-Schönlein purpura and angiotensin-converting enzyme inhibitors. Nephron 1994;67:117.
256. Larbre JP, Nicolas IF, Collet P, Larbre B, Llorca G. Kaposi's sarcoma in a patient with rheumatoid arthritis: possible responsibility of captopril in the development of lesions. J Rheumatol 1991;18:476-477.
257. Crantock L, Prentice R, Powell L. Cholestatic jaundice associated with captopril therapy. J Gastroenterol Hepatol 1991;6:528-530.
258. Hagley MT. Captopril-induced cholestatic jaundice. South Med J 1991;84: 100.
259. Balduf M, Steinkraus V, Ring J. Captopril associated lacrimation and rhinorrhea. Br Med J 1992;305:693.
260. Leaker B, Whitworth JA. Alopecia associated with captopril treatment. Aust N Z J Med 1984;14:866.
261. Bielory L, Lee SS, Holland CL, Jaker M. Long-acting ACE-inhibitor angioedema. Allergy Proc 1992;13:85-87.
262. Juarez Gimenez JC, Baena Diez IM, Carreras Soler MJ, Alegret F, Duran Pou S. Angioneurotic edema produced by enalapril (letter). Ann Pharmacother 1995;29:317.
263. Oike Y, Ogata Y, Higashi D, Matsumura T, Numata Y. Fatal angioedema associated with enalapril. Intern Med 1993;32:308-310.
264. Veneble RJ. Angioedema after long-term enalapril use. J Fam Pract 1992;34: 201-204.
265. Kubo SH, Cody RJ. Enalapril, a rash, and captopril (letter). Ann Intern Med 1984;100:616.
266. Carrington PR, Sanusi ID, Zahradka S, Winder PR. Enalapril-associated crythema and vasculitis. Cutis 1993;51:121-123.
267. Moots RJ, Keeling PJ, Morgan SH. Adult Schönlein Henoch purpura after enalapril. Lancet 1992;340:304-305.
268. Kanwar AJ, Dhar S, Ghosh S. Photosensitive lichenoid eruption due to enalapril (letter). Dermatology 1993;187:80.
269. Roten SV, Mainetti C, Donath R, Saurat JH. Enalapril-induced linchen planus-like eruption. J Am Acad Dermatol 1995;22:293-295.
270. Llop R, Gomez-Farran F, Figueras A, Capella D, Laporte JR. Gynecomastia associated with enalapril and diazepam. Ann Pharmacother 1994;28: 671-672.
271. Frangogiannis NG, Gangopadhyay S, Cate T. Pemphigus of the larynx and esophagus. Ann Intern Med 1995;122:803-804.
272. Shelton RM. Pemphigus foliaceous associated with enalapril. J Am Acad Dermatol 1991;24:503-504.
273. Mullins PD, Choudhury SL. Enalapril and bullous eruptions. Br Med J 1944; 309:1411.
274. Smith EP, Taylor TB, Meyer LJ, Zone JJ. Antigen identification in drug-induced bullous pemphigoid. J Am Acad Dermatol 1993;29:879-882.
275. Rees RS, Bergman J, Ramirez-Alexander R. Angioedema associated with lisinopnl. Am J Emerg Med 1992;10:321-322.
276. Frontera V, Piecuch JF. Multiple episodes of angioedema associated with lisinopril, an ACE inhibitor. J Am Dent Assoc 1995;126:217-220.
277. Savino I.B, Haushalter NM. Lisinopril-induced "scalded mouth syndrome." Ann Pharmacother 1992;22:1381-1382.
278. Ito K, Ito K, Sawada Y, Kamei I, Misawa M, Iga T. Toxicodynamic analysis of cough and inflammatory reactions by angiotensin-converting enzyme inhibitors in guinea pig. J Pharmacol Exp Ther 1995;275:920-925.
279. Acker CG, Greenberg A. Angioedema induced by the angiotensin II blocker losartan (letter). N Engl J Med 1995;333:1572.
280. Viraben R, Lamant L, Brousset P. Losartan-associated atypical cutaneous lymphoid hyperplasia (letter). Lancet 1997;350:1 366.
281. Hoff JV, Beatty PA, Wade JL. Dermal necrosis from dobutamine. N Engl J Med 1979;300:1280.
282. Wu CC, Chen WJ, Cheng JJ, Hsieh YY, Lien WP. Local dermal hypersensitivity from dobutamine hydrochloride injection. Chest 1991;99:1547-1548.
283. Cernck PK. Dermal cellulitis: a hypersensitivity reaction from dobutamine hvdrochloride (letter). Ann Pharmacother 1994;28:964.
284. McCauley CS, Blumenthal MS. Dobutamine and pruritus of the scalp. Ann Intern Med 1986;105:966.
285. Ross M. Dopamine-induced localized cutaneous vasoconstriction and piloerection. Arch Dermatol 1991;127:586-587.
286. Oglesby JE, Baugh JH. Tissue necrosis due to norepinephrinc. Am J Surg 1968;115:408-412.
287. Bhattacharya SK, Polk JW. Bilateral symmetrical gangrene of all toes: complication of infusion of vasopressor agent in a patient with pre-existing cold injury in both feet. Int Surg 1973;58:202-203.
288. Haves MA, Yau EH, Hinds CJ. Symmetrical peripheral association with noradrenaline administration. Intensive Care Med 1992;18:433-436.
289. Miller RM. Cutaneous ischemia caused by local anesthesia containing a vasoconstrictor. J Dermatol Surg Oncol 1994;20:222-223.
290. McCauley WA, Gerace RV, Scilley C. Treatment of accidental digital injection of epinephrinc. Ann Emery Med 1991;20:665-668.
291. Wilhelmi BJ, Blackwell SJ, Miller J, Mancoll JS, Phillips LG. Epinephrine in digital blocks: revisited. Ann Plast Surg 1998;41:410-414.
292. Bjornberg A, Gisslen H. Thiazides: a cause of necrotizing vasculitis? Lancet 1965;2:982-983.
293. Bar-On H, Eisenberg S, Eliakim M. Clinical experience with ethacrynic acid, with reference to a possible complication of the Henoch-Schönlein type. Isr J Med Sci 1967;3:113-118.
294. Thestrup-Pedersen K. Adverse reactions in the skin from antihypertensive drugs. Dan Med Bull 1987;34:3-5.
295. Burry JN, Lawrence JR. Phototoxic blisters from high furosemide dosage. Br J Dermatol 1976;94:495-499.
296. Gibson TP, Blue P. Erythema multiforme and furosemide therapy. JAMA 1970;212:1709.
297. Fellner MJ, Katz JM. Occurrence of bullous pemphigoid after furosemide therapy. Arch Dermatol 1976;112:75-77.
298. Breier F, Fieldmann R, Pelzl M, Gschnait F. Pseudoporphyria cutanea tarda induced bv furosemide in a patient undergoing peritoneal dialysis. Dermatology 1998;197:271-273.
299. Harber LC, Lashinsky AM, Baer RL. Photosensitivity due to chlorothiazide and hydrochiorothiazide. N Engl J Med 1959;261:1378-1381.
300. Addo HA, Ferguson J, Frain-Bell W. Thiazide-induced photosensitivity: a study of 33 subjects. Br J Dermatol 1987;116:749-760.
301. Robinson HN, Morison WL, Hood AF. Thiazide diuretic therapy and chronic photosensitivity. Arch Dermatol 1985;121:522-524.
302. Reed BR, Huff JC, Jones SK, Orton PW, Lee LA, Norris DA. Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med 1985;103:49-51.
303. Wollenberg A, Meurer M. Thiazide diuretic-induced subacute cutaneous lupus erythematosus. Hautarzt 1991;42:709-712.
304. Goodrich AL, Kohn SR. Hydrochlorothiazide-induced lupus erythematosus: a new variant? J Am Acad Dermatol 1993;28:1001-1002.
305. Goette DK, Beatrice E. Erythema annulare centrifugum caused by hydrochiorothiazide-induced interstitial nephritis. Int J Dermatol 1988;27:129-130.
306. Jaffe MO, Kierland RK. Purpura due to chlorothiazide. JAMA 1958;168: 2264-2265.
307. Ball P. Thrombocytopenia and purpura in patients receiving chlorothiazide and hydrochlorothiazide. JAMA 1960;173:663-665.
308. Greenblatt DJ, Koch-Weser J. Adverse reactions to spironolactone. JAMA 1993;225:40-43.
309. Schon MP, Tebbe B, Trautmann C, Orfanos CE. Lichenoid drug eruption induced by spironolactone (letter). Acta Derm Venereol 1994;74:476.
310. Danby FW. Spironolactone. J Am Acad Dermatol 1992;26:137.
311. Shaw J. Spironolactone in dermatology therapy. J Am Acad Dermatol 1991; 24:236-243.
312. Grange F, Scrivener Y, Koessler A, Straub P, Guillaume JC. Spironolactone-induced pemphigoid. Ann Dermatol Venereol 1997;124:700-702.
313. Byrd DR, Ahmed I. Photosensitive lichenoid reaction to torsemide, a loop diuretic. Mayo Clin Proc 1997;72:930-931.
314. Darken M, McBurney EI. Subacute cutaneous lupus erythematosus-likc drug eruption due to combination diuretic hydrochlorothiazide and triamterene. J Am Acad Dermatol 1988;18:38-42.
315. Baume P, Ratcliffe FJ, Corry JR. Triamterene, a new natriuretic agent. Am J Med Sci 1963;245:668-675.
316. Van Joost T, Faber WR, Manuel HR. Drug-induced anogenital cicatricial pemphigoid. Br J Dermatol 1980;102:715-718.
317. Witman G, Davis R. A lupus crythematosus syndrome induced by clonidine hydrochloride. R I Med 1981;164:147-150.
318. Wilkin J. Exacerbation of psoriasis during clonidine therapy (letter). Arch Dermatol 1981;117:4.
319. Wiser TH, Kazakis AM, LaCivita CL. Transdermal clonidine: an association with recurrent herpes simplex and hyperpigmentation. J Am Acad Dermatol 1987;17:143-144.
320. Dick JBC, Northridge DB, Lawson AAH. Skin reactions to long-term transdermal clonidine. Lancet 1987;1:516.
321. Corazza M, Mantovani L, Virgili A, Strumia R. Allergic contact dermatitis from a clonidine transdermal delivery system. Contact Dermatitis 1995;32: 246.
322. McChesney JA. Preventing contact dermatitis caused by a transdermal clonidine patch. West J Med 1991;154:736.
323. Polster AM, Warner MR, Camisa C. Allergic contact dermatitis from transdermal clonidine in a patient with mycosis fungoides. Cutis 1999;63:154-155.
324. McMahon FG, Weber MA. Allergic skin reactions to transdermal clonidine. Lancet 1983;2:850-851.
325. Kuan P. Dangers of diazoxide. Br Med J 1973;1:114.
326. Lievre M, Azoulay S, Lion L, Morand S, Girre JP, Boissel JP. A dose-effect study of beraprost sodium in intermittent claudication. J Cardiovasc Pharmacol 1996;27:788-793.
327. Lee SL, Rivero I, Siegel M. Activation of systemic lupus erythematosus by drugs. Arch Intern Med 1966;117:620-626.
328. Hofstra AH. Metabolism of hydralazine: relevance to drug-induced lupus. Drug Metab Rev 1994;26:485-505.
329. Yonga GD. Low dose hydralazine induced lupus. East Afr Med J 1992;69: 649-650.
330. Peterson II. Hydralazine-induced systemic lupus erythematosus presenting as pyoderma gangrenosum-like ulcers. J Am Acad Dermatol 1984;10:379-384.
331. Kissin MW, Williamson RCN. Hydralazine-induced SLE-like syndrome presenting as a leg ulcer. Br Med J 1979;2:1330.
332. Petty R, Medley DRK. Cutaneous manifestations of hydralazine toxicity. Br Med J 1980;280:482.
333. Sequeira W, Polinsky RB, Alrenga DP. Neutrophilic dermatosis (Sweet's syndrome). Am J Med 1986;81:558-560.
334. Servitje O, Ribera M, Juanola X, Rodriguez-Morena J. Acute neutrophilic dermatosis associated with hydralazine induced lupus. Arch Dermatol 1987; 123:1435-1436.
335. Korkij W, Soltani K. Fixed drug eruptions. Arch Dermatol 1984;120:520-524.
336. Wilkin JK. Vasodilator rosacca. Arch Dermatol 1980;116:598.
337. Holt PJA, Navaratnam A. Lichenoid eruption due to methyldopa. Br Med J 1974;3:234.
338. Vaillant L, Le Marchand D, Grognard C, Hocine R, Lorette G. Photosensitivity to methyldopa. Arch Dermatol 1988;124:326-327.
339. Church R. Eczema provoked by methyldopa. Br J Dermatol 1974;91:373-378.
340. Wells JD, Kurtay M, Lochner JG, George WL. Granulomatous skin lesions and alpha-methyl dopa. Ann Intern Med 1974;81:701-702.
341. Mackie BS. Drug-induced ulcer of the lip. Br J Dermatol 1967;79:106-110.
342. Rausing A, Rosen U. Black cartilage after therapy with levodopa and methyldopa. Arch Pathol Lab Med 1994;118:531-535.
343. Wolf R, Tamir A, Werbin N, Brenner S. Methyldopa hypersensitivity syndrome. Ann Allergy 1993;71:166-168.
344. Burton JL, Marshall A. Hypertrichosis due to minoxidil. Br J Dermatol 1979; 101:593-595.
345. DiSantis DJ, Flanagan J. Minoxidil-induced Stevens-Johnson syndrome. Arch Intern Med 1981;141:1515.
346. Ackerman BH, Townsend ME, Golden W, Bryan AB. Pruritic rash with actinic keratosis and impending exfoliation in a patient with hypertension managed with minoxidil. Drug Intell Clin Pharm 1988;22:702-703.
347. Kounis NG, Zavras GM, Papadaki PJ, Soufras GD, Poulos EA, Goudevenos J, et al. Allergic reactions to local glyceryl trinitrate administration. Br J Clin Pract 1996;50:437-439.
348. Fisher AA, Dec WD. Dermatitis due to transdermal therapeutic systems. Cutis 1984;34:526-531.
349. Torres V, Lopes JC, Leite L. Allergic contact dermatitis from nitroglycerin and estradiol transdermal therapeutic systems. Contact Dermatitis 1992;26:53-54.
350. de la Fuente Prieto R, Armentia Medina A, Diez Perez JM. Contact dermatitis from nitroglycerin. Ann Allergy 1994;72:344-346.
351. Hendricks AA, Dec WD. Contact dermatitis due to nitroglycerine ointment. Arch Dermatol 1979;115:853-855.
352. Wutshert R, Piletta P, Bounameaux H. Adverse skin reactions to low molecular weight heparins: frequency, management, and prevention. Drug Safety 1999; 20:515-525.
353. Plath I, Schulze R, Barz D, Krammer B, Steiner M, Anders O, Mach J. Necrotizing skin lesions induced by low-molecular-weight heparin after total knee arthroplasty. Arch Orthof Trauma Surg 1997;116:443-445.
354. Cabanas R, Caballero MT, Lopez-Serrano MC, Diaz R, Contreras J, Barranco P, Moreno-Ancillo A. Delayed hypersensitivity to enoxaparin. J Invest Allerg Clin Immunol 1998;8:383-384.
355. Gonzalo Garijo MA, Revenga Arranz F. Type IV hypersensitivity to subcutaneous heparin: a new case. J Invest Allerg Clin Imnmnol 1996;6:338-391.
356. Katz Y, Goldberg N, Kivity S. Localized periorbital edema induced by aspirin. Allergy 1993;45:366-369.
357. Baker H, Moore-Robinson M. Cutaneous responses to aspirin and its derivatives. Br J Dermatol 1970;82:319-321.
358. Brannen M, Forbes AE. Salicylate sensitivity. Tex J Med 1966;62:58-60.
359. Zhu DX, Zhao JL, Mo L, Li HL. Drug allergy: identification and characterization of IgE-reactivities to aspirin and related compounds. J Invest Allerg Clin Immunol 1997;7:160-168.
360. Shelley WB. Birch pollen and aspirin psoriasis. JAMA 1964;189:985-988.
361. Santamaria A, Romani J, Souto JC, Lopez A, Matco J, Fontcuberta J. Skin necrosis at the injection site induced by low-molecular weight heparin: case report and review. Dermatology 1998;196:264-265.
362. Lefebvre I, Delaporte E, Dejobert Y, Catteau B, Piette F, Bergoend H. Enoxaparin-induced cutaneous necrosis localized on insulin lipodystrophies. Ann Dermatol Venereol 1997;124:397-400.
363. Mendez J, Sanchis ME, de la Fuente R, Stolle R, Vega JM, Martinez C, et al. Delayed-type hypersensitivity to subcutaneous enoxaparin. Allergy 1998;53: 999-1003.
364. Koch P, Hindi S, Landwehr D. Delayed allergic skin reactions due to subcutaneous heparin-calcium, enoxaparin-sodium, pentosan polysulfate and acute skin lesions from systemic soelium-heparin. Contact Dermatitis 1996;34:156-158.
365. Hirschboeck JS, Madison FW, Pisciotta AV. Alopecia and other toxic effects of heparin and synthetic heparinoids. Am J Med Sci 1965;227:279-282.
366. Chernoff AI. Anaphylactic reaction following injection of heparin. N Engl J Med 1950;242:315-319.
367. Oden M, Oliven A. Urticaria and angioedema induced by low-molecular-weight heparin. Lancet 1992;340:972-973.
368. Warkentin TE. Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol 1998;35:9-16.
369. Chong BH. Heparin-induced thrombocytopenia. Aust N Z J Med 1992;22: 145-152.
370. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;32: 1330-1335.
371. Aster RH. Heparin-induced thrombocytopenia and thrombosis. N Engl J Med 1995;332:1374-1376.
372. Angus B, Abadir AR, Chaudry MR, Gintautas J. Heparin-induced thrombocytopenia. Proc West Pharmacol Soc 1994;37:101-102.
373. Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. Prog Hemost Thromb 1991;10:1-34.
374. Gross AS, Thompson FL, Arzubiaga MC, Graber SE, Hammer RD, Schulman G, et al. Heparin-associated thrombocytopenia and thrombosis presenting with livedo reticularis. Int J Dermatol 1993;32:276-279.
375. Boon DM, Michiels JJ, Stippe I, Van Vilet HH. Heparin-induced thrombocytopenia and antithrombotic therapy (letter). Lancet 1994;344:1296.
376. Phillips DE, Payne DK, Milis GM. Hcparin-induced thrombotic thrombocytopenia. Ann Phamacother 1994;28:43-46.
377. Demasi R, Bode AP, Knupp C, Bogey W, Powell S. Heparin-induced thrombocytopenia. Am Surg 1994;60:26-29.
378. Rama BN, Haake RE, Bander SJ, Ghasem-Zadeh A, Gorla C. Heparin-flush associated thrombocytopenia-induced hemorrhage: a case report. Nebr Med J 1991;76:392-394.
379. Gruel Y, Rupin A, Watier H, Vigier S, Bardos P, Leroy J. Anticardiolipin antibodies in heparin associated thrombocytopenia. Thromb Res 1992;67:601-606.
380. Kelly RA, Gelfand JA, Pincus SH. Cutaneous necrosis caused by systemically administered heparin. JAMA 1981;246:1582-1583.
381. Gold JA, Watters AK, O'Brien E. Coumadin versus heparin necrosis. J Am Acad Dermatol 1987;16:148-149.
382. Levine LE, Bernstein JE, Soltani K, Medenica MM, Yung CW. Heparin induced necrosis unrelated to injection sites: a sign of potentially lethal complications. Arch Dermatol 1983;119:400-403.
383. Leblanc M, Roy LE, Legault L, Dufresne LR, Morin C, Thuot C. Severe skin necrosis associated with heparin in hemodialysis. Nephron 1994;68:133-137.
384. Real E, Grau E, Rubia M, Torrecilla T. Skin necrosis after subcutaneous low molecular weight heparin injection. Am J Hematol 1995;49:253-254.
385. Ojeda E, Perez MC, Mataix R, Arbelo A, Jimenez S, Campo C, Balda I. Skin necrosis with a low molecular weight heparin. Br J Haematol 1992;82:620.
386. Jumphries JE, Kaplan DM, Bolton WK. Heparin skin necrosis: delayed occurrence in a patient on hemodialysis. Am J Kidney Dis 1991;17:233-236.
387. Yates P, Jones S. Heparin skin necrosis: an important indicator of potentially fatal heparin hypersensitivity. Clin Exp Dermatol 1993;18:138-141.
388. Harenberg J, Huhle G, Wang L, Hoffmann U, Bayerl Ch, Kerowgan M. Association of heparin-induced skin lesions, intracutaneous tests, and heparin-induced IgG. Allergy 1999;54:473-477.
389. O'Toole RD. Heparin: adverse reaction. Ann Intern Med 1973;79:759.
390. Koch P, Bahmer FA, Schafer A. Tolerance of intravenous low-molecular-weight heparin after eczematous reaction to subcutaneous heparin. Contact Dermatitis 1991;25:205-206.
391. Valsecchi R, Rozzoni M, Cainelli T. Allergy to subcutaneous heparin. Contact Dermatitis 1992;26:129-130.
392. Mathelier-Fusade P, Deschamps A, Abuaf N, Leynadier F. Skin reactions to heparin: immunologic and clinical features. Presse Med 1995;24:323-325.
393. Mohammed KN. Symmetric fixed eruption to heparin (letter). Dermatology 1995;190:91.
394. Bircher AJ, Itin PH, Buchner SA. Skin lesions, hypereosinophilia, and subcutaneous heparin. Lancet 1994;343:861.
395. Giustolisi R, Guglielmo P, di Raimondo F, Cacciola E, Stagno F. Hypereosinophilia and subcutaneous heparin. Lancet 1993;342:1371.
396. Fox JG, Waili RK, Jaffray B, Simpson HK. Calcified subcutaneous nodules due to calcium heparin injections in a patient with chronic renal failure. Nephrol Dial Transpl 1994;9:187-188.
397. Yosipovitch G, Rechavia E, Feinmesser M, David M. Adverse cutaneous reactions to ticlopidine in patients with coronary stents. J Am Acad Dermatol 1999;41:473-476.
398. Whetsel TR, Bell DM. Rash in patients receiving ticlopidine after intracoranary stent placement. Pharmacotherapy 1999;19:288-231.
399. Nalbandian RM, Mader IJ, Barret JL. Petechiae, ecchymoses, and necrosis of skin induced by coumadin congeners. JAMA 1965;192:107-112.
400. Verhagen H. Local hemorrhage and necrosis of the skin and underlying tissues during anticoagulant therapy with dicumarol and dicumarcyl. Acta Med Scand 1954;148:453-462.
401. Flood EP, Redish MH, Bociek SJ. Thrombophlebitis migrans disseminate: report of a case in which gangrene of the breast occurred. N Y State J Med 1943;43:1121-1124.
402. Sternberg MC, Pettyjohn FS. Warfarin sodium-induced skin necrosis. Ann Emerg Med 1995;26:94-97.
403. Cole MS, Minifee PK, Wolma FJ. Coumarin necrosis: a review of the literature. Surgery 1988;103:271-276.
404. Kwong P, Roberts P, Prescott SM. Dermatitis induced by warfarin. JAMA 1978;239:1884-1885.
405. Hermes B, Haas N, Henz BM. Immunopathological events of adverse cutaneous reactions to coumarin and heparin. Acta Derm Venereol 1997;77:35-38.
406. Eby CS. Warfarin-induced skin necrosis. Hematol Oncol Clin North Am 1993; 7:1291-1300.
407. Anderson DR, Brill-Edwards P, Walker I. Warfarin-induced skin necrosis in two patients with protein S deficiency: successful reinstatement of warfarin therapy. Hemostasis 1992;22:124-128.
408. Defranzo AJ, Marasco P, Argenta LC. Warfarin-induced necrosis of the skin. Ann Plast Surg 1995;34:203-208.
409. McKnight JT, Maxwell AJ, Anderson RL. Warfarin necrosis. Arch Fam Mcti 1992;1:105-108.
410. Fernandez-Fernandez FJ, Garrido JA. Severe adverse cutaneous reactions to drugs. N Engl J Med 1995;332:959-960.
411. Soisson AP, Vu KK, Brittain PC, Chamales I. An unusual cutaneous reaction to anticoagulant therapy. Milit Med 1994;159:252-253.
412. Park S, Schroeter AL, Park YS, Fortson J. Purple toes and livedo reticularis in a patient with cardiovascular disease taking coumadin: cholesterol emboli associated with coumadin therapy. Arch Dermatol 1993;129:777-780.
413. Adams CW, Pass BJ. Extensive dermatitis due to warferin sodium. Circulation 1960;22:947-948.
414. Schiff BL, Kern AB. Cutaneous reactions to anticoagulants. Arch Dermatol 1968;98:136-137.
415. Antony SJ, Krick SK, Menta PM. Unusual cutaneous adverse reaction to warfarin therapy. South Med J 1993;86:1413-1414.
416. Sheps SG, Clifford RW. Urticaria after administration of warfarin sodium. Am J Cardiol 1959;3:118-120.
417. Feder W, Auerbach R. "Purple toes": an uncommon sequelae of oral coumarin drug therapy. Ann Intern Med 1961;55:911-917.
418. Baker H, Levene GM. Cutaneous reactions to anticoagulants. Br J Dermatol 1969;81:236-238.
419. Khanlou H, Malhotra G, Khanlou N, Eiger G, Frechie P. Massive subfascial hematoma after alteplase therapy for acute myocardial infarction. Am J Med Sci 1999;317:53-54.
420. Adorati M, Pizzolitto S, Franzon R, Vallone C, Artero M, Moro A. Cholesterol embolism and acute interstitial nephritis: two adverse effects of streptokinase thrombolytic therapy in the same patient. Nephrol Dial Transplant 1998;13: 1262-1264.
421. Geraets DR, Hoehns JD, Burke TG, Grover-McKay M. Thrombolytic-associated cholesterol emboli syndrome: case report and literature review. Pharmacotherapy 1995;15:441-450.
422. Krasovec M, Elsner P, Burg G. Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors. Dermatology 1993;186:248-252.
423. Wong SS. Stevens-Johnson syndrome induced by clofibrate (letter). Acta Derm Venereol 1994;74:475.
424. Marguery MC, Chouini-Lalanne N, Ader JC, Paillons N. Comparison of the DNA damage photoinduced by fenofibrate and ketoprofen, two phototoxic drugs of parent structure. Photochemistry Photobiol 1998;68:679-684.
425. Marguery MC, Saved FE, Rakotondrazafy J, Saqi R, Samalens G, Gorguet B, Bazex J. Photoallergy and photoaggravation induced by fenofibrate: cross photoreaction and transient light reaction. Eur J Dermatol 1995;5:204-207.
426. Smith GW, Hurst NP. Vasculitis, Raynaud's phenomenon, and polyarthritis associated with gemfibrozil therapy. Br J Rheumatol 1993;32:84-85.
427. Ahmed S. Lovastatin-induced lupus erythematosus. Arch Intern Med 1991; 151:1667-1668.
428. Jungnickel PW, Maloley PA, Vander Tuin EL, Peddicord TE, Campbell JR. Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions. J Gen Intern Med 1997;12:591-596.
429. Stals H, Vercammen C, Peeters C, Morren MA. Acanthosis nigracans caused by nicotinic acid: case report and review of the literature. Dermatology 1994; 189:203-206.
430. Charman RC, Matthews LB, Braculer C. Nicotinic acid in the treatment of hypercholesterolemia. Angiology 1972;23:29-35.
431. Mehregan DR, Mehregan DA, Pakideh S. Cheilitis due to treatment with simvastatin. Cutis 1998;62:197-198.
432. Morimoto K, Kawada A, Kiruma M. Photosensitivity to simvastatin with an unusual response to photopatch and photo tests. Contact Dermatitis 1995;33: 274.